secwatch.observer — SEC 8-K summary
======================================

Issuer:     CEL SCI CORP (CVM)
CIK:        0000725363
Form:       8-K
Filed at:   2022-09-13T23:59:59+00:00
Accession:  0001654954-22-012408
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEL-SCI Phase 3 Multikine at ESMO: 45 responses, all in treatment group (1 in 100B chance), >3x OS benefit
--------------------------------------------------------------------------------

- 45 RECIST neoadjuvant responses including 5 complete; all exclusive to Multikine groups (1 in 100 billion chance).
- Overall survival >3x longer for responders vs non-responders.
- Early tumor response (pre-surgery) noted only in Multikine groups, not control; prognostic and predictive for OS.
- Biomarker analysis: low tumor PDL1, high immune cell density, specific ratios predict Multikine efficacy.
- Data from the largest Phase 3 study ever in newly diagnosed locally advanced head and neck cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/725363/000165495422012408/0001654954-22-012408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/725363/000165495422012408/cvm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-012408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer